164 related articles for article (PubMed ID: 36856812)
21. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
[TBL] [Abstract][Full Text] [Related]
23. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
[TBL] [Abstract][Full Text] [Related]
24. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
25. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
27. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
Zhao LM; Huang JN; Qiu M; Ding LL; Zhan ZL; Ning J
Medicine (Baltimore); 2021 Oct; 100(39):e27362. PubMed ID: 34596148
[TBL] [Abstract][Full Text] [Related]
28. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
[TBL] [Abstract][Full Text] [Related]
29. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP
Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004
[TBL] [Abstract][Full Text] [Related]
30. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
32. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
Sinha B; Ghosal S
Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
[TBL] [Abstract][Full Text] [Related]
33. Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Hu J; Chen L
Prim Care Diabetes; 2021 Apr; 15(2):227-233. PubMed ID: 32888896
[TBL] [Abstract][Full Text] [Related]
34. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
36. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Suzuki Y; Kaneko H; Okada A; Itoh H; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Yasunaga H; Komuro I
Cardiovasc Diabetol; 2022 May; 21(1):67. PubMed ID: 35585590
[TBL] [Abstract][Full Text] [Related]
38. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
Pitt B; Steg G; Leiter LA; Bhatt DL
Cardiovasc Drugs Ther; 2022 Jun; 36(3):561-567. PubMed ID: 34750713
[TBL] [Abstract][Full Text] [Related]
39. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
